SCHEMBL4501877

SCHEMBL4501877

CCN(CC)C(=O)COc1cccc(Cl)c1CC1CCN(C2CCCCC2)C1=O

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSD11B1 P28845 1/20 0.44
SIGMAR1 Q99720 3/20 0.42
TSHR P16473 3/20 0.40
GAA P10253 2/20 0.35
KMT2A Q03164 2/20 0.35
POLB P06746 2/20 0.35
KCNJ6 P48051 1/20 0.35
KCNJ5 P48544 1/20 0.35
KCNJ3 P48549 1/20 0.35
KDM4E B2RXH2 4/20 0.35
ALDH1A1 P00352 3/20 0.35
TDP1 Q9NUW8 2/20 0.35
SMN1; SMN2 Q16637 2/20 0.35
LMNA P02545 1/20 0.35
NPSR1 Q6W5P4 1/20 0.35
L3MBTL1 Q9Y468 1/20 0.35
SMO Q99835 1/20 0.34
HPGD P15428 1/20 0.34
HSD17B10 Q99714 1/20 0.34
LTB4R Q15722 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4523062 0.88 HSD11B1 (0.48) HSD11B1SIGMAR1GAAKMT2APOLB
SCHEMBL4513738 0.88 HSD11B1 (0.52) HSD11B1TSHRGAAKMT2APOLB
SCHEMBL4506063 0.83 TSHR (0.38) SIGMAR1TSHRGAAKMT2AALDH1A1
SCHEMBL4516365 0.81 HSD11B1 (0.54) HSD11B1SIGMAR1TSHRGAAKMT2A
SCHEMBL4516411 0.81 HSD11B1 (0.47) HSD11B1KCNJ5KCNJ3LMNA
SCHEMBL5541309 0.81 HSD11B1 (0.49) HSD11B1TSHRGAAKMT2AALDH1A1
SCHEMBL4526129 0.80 SIGMAR1 (0.42) HSD11B1SIGMAR1TSHRGAAKMT2A
SCHEMBL4508316 0.79 HSD11B1 (0.49) HSD11B1TSHRGAAKMT2APOLB
SCHEMBL3553955 0.79 HSD11B1 (0.64) HSD11B1SIGMAR1KMT2APOLBALDH1A1
SCHEMBL3002320 0.76 HSD11B1 (0.57) HSD11B1SIGMAR1KMT2APOLBALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090264650-A1 Prophylactic/Therapeutic Agent for Diabetes TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-10-22 US disclosed
US-20090264650-A1 Prophylactic/Therapeutic Agent for Diabetes TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-10-22 US disclosed
US-20090264650-A1 Prophylactic/Therapeutic Agent for Diabetes TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-10-22 US disclosed
EP-1864971-A1 PROPHYLACTIC/THERAPEUTIC AGENT FOR DIABETES Takeda Pharmaceutical Company Limited (JP) 2007-12-12 EP disclosed
EP-1864971-A1 PROPHYLACTIC/THERAPEUTIC AGENT FOR DIABETES Takeda Pharmaceutical Company Limited (JP) 2007-12-12 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090264650-A1 Prophylactic/Therapeutic Agent for Diabetes HSD11B1, HSD17B1, HSD11B2 HSD11B1 1/4885SIGMAR1 2409/4885TSHR 3390/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.